In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

• Ultra-low PSA Response (<0.02 ng/mL) with Darolutamide Plus ADT in ARANOTE Correlates with Greatly Improved Clinical Outcomes Interactive Poster Session: IP26-07; April 29, 9:30-11:30 a.m. PDT ...

Kidney cancer is a commonly diagnosed cancer in adults, and clear cell renal cell carcinoma (ccRCC) is the most common histological subtype. Immune checkpoint inhibitors have revolutionized care for ...

Neuroendocrine prostate cancer (NEPC) is rare at the time of initial diagnosis but much more common in patients treated with the combination of androgen deprivation therapy (ADT) and androgen receptor ...

Although diagnostic efficacy of multiparametric magnetic resonance imaging (MRI) in identifying index lesions (ILs) in prostate cancer (PCa) patients is well established, challenges arise when ...

Radical cystectomy is an effective treatment option for high-risk, non-muscle-invasive bladder cancer (NMIBC) to prevent progression. A recent 12-year multicenter study evaluated survival outcomes of ...

Dry Mouth Prevention and Management for PSMA Radioligand Therapy "Presentation" - Sue Yom ...

How are we Getting Paid for Theranostics and Dosimetry? "Presentation" - Denise Merlino ...

Natural killer (NK) cells are innate immune lymphocytes that play a crucial role in tumor surveillance and control. In recent years, NK cell-based therapies for cancer have garnered significant ...

Renal cell carcinoma (RCC) patients in clinical T1 RCC generally exhibit a favorable prognosis. Guidelines recommend partial nephrectomy (PN), also for cT1b RCCs. Despite a favorable prognosis, there ...

Prostate cancer (PCa) remains the most common non-cutaneous cancer among men in Europe, with treatment advances improving mortality outcomes. Radical prostatectomy (RP) is a key treatment option for ...

Metastatic penile cancer (PC) continues to have a poor prognosis due to inadequate treatment options. Enfortumab vedotin (EV) and sacituzumab govitecan (SG) are antibody-drug conjugates (ADCs) that ...